In an uncontrolled study, vancomycin pharmacokinetics were determined in four normal (total body weight [TBW], 65.9 to 89.1 kg) and six morbidly obese (TBW, 111.4 to 226.4 kg) subjects. The morbidly obese subjects were investigated 3 to 4 h after gastric bypass surgery. Mean terminal half-lives, volumes of distribution, and total body clearances for the normal controls and the morbidly obese subjects were 4.8 h, 0.39 liter/kg, and 1.085 ml/min per kg versus 3.2 h, 0.26 liter/kg TBW, and 1.112 ml/min per kg TBW. The mean terminal half-life and volume of distribution values were significantly different between the two groups. Strong correlations were found between TBW and both volume of distribution (correlation coefficient, 0.943) and total body clearance (correlation coefficient, 0.981). These results implied that TBW should be used to calculate vancomycin doses for morbidly obese patients. This was supported by the finding that there was no significant difference in the daily dose (in milligrams per kilogram per day) required to produce an average steady-state concentration of 15 ,ug/ml in the two groups (23.4 ± 1.5 mg/kg per day for normal weight subjects and 24.0 ± 3.4 mg/kg per day TBW for the postsurgery morbidly obese subjects). Therefore, the morbidly obese required higher total doses (in milligrams per day) than did normal weight subjects to achieve the same mean steady-state concentrations. In addition, normal weight and morbidly obese subjects had similar volumes of the central compartment (7.7 and 6.4 liters, respectively). To avoid high transient peak concentrations which could occur when obese patients are given larger total doses (in milligrams per day), maintenance doses may be given at more frequent intervals. The shorter mean terminal half-lives observed in morbidly obese patients allows more frequent dosing without excessive accumulation.
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Vancomycin is a narrow-spectrum, bactericidal antibiotic primarily used for the treatment of penicillinase-producing staphylococci (12) . Ototoxicity and nephrotoxicity remain the most important side effects associated with vancomycin therapy. Ototoxicity has occurred at serum concentrations between 80 and 100 ,ug/ml (11) but rarely occurs when serum concentrations are below 30 ,ug/ml (17) . The minimum inhibitory concentration and minimum bactericidal concentration ranges for Staphylococcus aureus are 1.56 to 3.12 ,ug/ml and 1.56 to 6.25 ,ug/ml, respectively (10 and frozen at -5C until assayed. A 24-h Clc, determination was initiated at the time of vancomycin administration, with a serum creatinine concentration obtained at the midpoint of the urine collection.
Assay. A commercially available radioimmunoassay (Monitor Science) was used to determine serum concentrations of vancomycin. The lower limit of sensitivity was 0.5 ,g/ml. The within-run coefficient of variation was determined on three different occasions with five observations of 4 and 32 ,ug/ml. The coefficient of variation values were 7.7, 4.3, and 3.0%o for the lower concentration and 2.8, 2.7, and 4.1% for the higher concentration. A complete set of standards was used with each run. Serum and urine creatinine concentrations were performed by the clinical chemistry laboratory with the modified Jaffe reaction-kinetic method on a centrifugal analyzer.
Pharmacokinetics. The vancomycin serum concentration-time profile declined in a triexponential manner for both the normal and morbidly obese subjects.
Individual postinfusion data sets were computer-fitted with the SAAM 23 nonlinear least-squares regression program (3) to the following equation: C = P'e-7" + A'e-' + B'e-, where C is concentration and t is time. A weighting factor of 1/(CObe,f,ed)2 was used. 
RESULTS
The pharmacokinetic constants and selected vancomycin serum concentrations of individual patients are shown in Tables 2 and 3 . Mean 13 values (± standard deviation) of 0.220 ± 0.040 h-1 and 0.146 ± 0.012 h-1 were observed for the morbidly obese and normal subjects, respectively; these values were significantly different (Student's t test, P < 0.02). The half-lives tlip calculated from these mean values were 3.2 and 4.8 h. A plot of P versus Clcr (in milliliters per minute) showed a correlation coefficient (r) of 0.721, which is statistically significant (P < 0.05).
Morbidly obese and normal subjects had aver- morbidly obese subjects (6.4 ± 3.2 liters) and subjects adjusted for TBW; there was a signifinormal subjects (7.7 ± 2.2 liters). cant difference between the ClT calculated in Mean ClT values for the morbidly obese were normal subjects and that found in morbidly 1.112 ± 0.160 mlmin per kg TBW or 2.897 ± obese patients adjusted for IBW. Morbidly 0.611 m/min per kg IBW, whereas normal pa-obese subjects had a mean ClT (187.50 ml/min) tients had a ClT of 1.085 ± 0.071 ml/min per kg. that was significantly larger than that found in No significant difference existed between CIT in normal subjects (80.78 mlmin). Figure 2 shows normal subjects and that of morbidly obese the strong correlation which exists between CIT (Fig. 1) . A very strong correlation also exists between ClT (in milliliters per minute) and TBW (Fig. 2) Renal function (indicated by Clcr) was significantly greater in the morbidly obese group compared with controls and was strongly correlative with TBW and body surface area. Similar increases in Cl, have been noted in morbidly obese subjects with normal serum creatinine values (0.5 to 1 mg/dl) who were not postsurgery patients (7) . The mean Clcr in these previously reported subjects was 160 ml/min (range, 132 to 264 ml/min) (7) . Therefore, it is unlikely that surgery had a substantial influence on Clcr. Increases in Clcr could be attributed to increases in the number or size of functioning nephrons or to increases in blood flow to the organ. Although kidney mass has been shown to increase with obesity (16), a morphological evaluation was not performed. Clcr values for all subjects studied ranged from 113 to 247 ml/min. The six morbidly obese subjects had Clcr values of 180 ± 44 ml/ min, whereas four normal subjects had values of 138 ± 28 mlmin. As would be expected with a drug predominantly eliminated by the kidney via glomerular filtration, a strong correlation was demonstrated between Clcr and ClT.
Caution should be exercised when our results are applied to patients. The morbidly obese subjects we investigated were in a postsurgical state, whereas the subjects did not undergo surgery. In this sense, the normal subjects may not be considered as a strict control group for the morbidly obese postsurgery subjects. We used IBW to normalize the morbidly obese subjects' pharmacokinetic parameters instead of lean body mass. Better correlations may exist between the subjects' kinetic parameters and lean body mass than were observed between the kinetic parameters and IBW. In addition, our results may not apply to patients who are slightly or moderately obese.
In summary, normal and morbidly obese subjects had similar V., ( 
